Skip to main content

Advertisement

Table 1 Patients’ characteristics (n = 74)

From: Comprehensive analysis of the influence of G-CSF on the biodistribution of 18F-FDG in lymphoma patients: insights for PET/CT scheduling

Characteristics  
Age (year), mean ± SD [min-max] 60 ± 14 [21;80]
Sex, n (%)
 Female 35 (47.3)%
 Male 39 (52.7)%
Age-adjusted IPI, n (%)
 0 8 (10.8)%
 1 28 (37.8)%
 2 24 (32.4)%
 3 14 (19.0)%
Deauville score at i-PET/CT, n (%)
 1 23 (31.1)%
 2 13 (17.6)%
 3 11 (14.9)%
 4 13 (17.6)%
 5 14 (18.9)%
Growth factor type (G-CSF), n (%)
 Filgrastim 52 (70.3)%
 Lenograstim 10 (13.5)%
 Pegfilgrastim 12 (16.2)%
First line of chemotherapy, n (%)
 R-CHOP 68 (91.9)%
 R-ACVBP 6 (8.1)%
Bone involvement*, n (%) 17 (23.0)%
Spleen involvement*, n (%) 8 (10.8)%
Liver involvement*, n (%) 1 (1.3)%
Baseline MATV (cc), mean ± SD 449.4 (732.0)%
  1. IPI International Prognostic Index, i-PET/CT interim PET/CT, MATV metabolic active tumour volume
  2. *Based on PET/CT analysis